PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. The company offers various services, including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. It also develops prepaid card solutions for corporate incentive and rewards, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, the company offers Co-Pay Assistance Program, a pharmaceutical payment card product; and Per Diem/Corporate Expense Payments that allows businesses, and nonÂprofits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, it provides Buy and Bill programs for patients to purchase directly from physician's office or through an infusion center for physician administered therapies; payment solution for source plasma collection centers; and PaySign Premier, a demand deposit account debit card, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and internationally. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. is based in Henderson, Nevada.
IPO Year:
Exchange: NASDAQ
Website: paysign.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $6.00 | Buy | Lake Street |
| 3/30/2022 | $4.00 | Mkt Perform | Barrington Research |
| 3/24/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 8/20/2021 | $3.50 | Neutral → Buy | DA Davidson |
| 8/19/2021 | Neutral → Buy | DA Davidson | |
| 8/12/2021 | $3.50 → $3.75 | Neutral → Buy | Ladenburg Thalmann |
Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Ladenburg Thalmann downgraded PaySign from Buy to Neutral
DA Davidson upgraded PaySign from Neutral to Buy and set a new price target of $3.50
DA Davidson upgraded PaySign from Neutral to Buy
Ladenburg Thalmann upgraded PaySign from Neutral to Buy and set a new price target of $3.75 from $3.50 previously
Ladenburg Thalmann upgraded PaySign from Sell to Neutral and set a new price target of $3.50
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G - Paysign, Inc. (0001496443) (Subject)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss its third quarter 2024 financial results at 5:00 p.m. Eastern time on Tuesday, November 5, 2024. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13749532 The replay will be available until February 5, 2025. To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. Eastern time on Frida
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing, today announced their participation in the Sidoti Micro-Cap Virtual Conference, taking place August 14-15, 2024. Jeff Baker, Paysign's Chief Financial Officer, will be available for one-on-one and small group meetings with investors during the event. Paysign is scheduled for a group presentation on Wednesday, August 14, at 4:00 p.m. EDT. To register or learn more about the conference, investors may visit the event website or visit the webinar registration page to attend the live group presentation. Forwar
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced they will be presenting at the Oppenheimer 27th Annual Technology, Internet & Communications Conference to be held August 12-14, 2024, through a virtual format. The focus of the virtual conference is to provide an expansive look across the dynamic sector of the world economy at existing and emerging technologies and provide potential investors the opportunity to evaluate public companies at the forefront of these technological innovations. Paysign's Chief Financial Officer, Jeff Baker, is sch
Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss second quarter 2024 earnings at 5:00 p.m. Eastern time on Wednesday, July 31, 2024. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13747519 The replay will be available until October 29, 2024. To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. Eastern time on Friday, July 26
RALEIGH, NC / ACCESSWIRE / June 21, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Summer Conference" is taking place on June 25-26, 2024.The conference begins on Tuesday, June 25, with Company presentations beginning at 9:30 a.m. Eastern Time.Company presentations will be webcast live online on Tuesday June 25. 1x1 Meetings are being held all-day Wednesday June 26 beginning at 8:00 a.m. Eastern Time.To sign up to listen to company presentations, register at the event website below:Event website: https://www.iaccessalpha.com/On Tuesday, June 25, the following companies will be presenting via webcast. All times are in ET.Presentation TimeOrganizationTicker9:30amEvaxion Biotech A/S view pr
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced Jeff Baker, Paysign's Chief Financial Officer, will speak at the Maxim Fintech Virtual Symposium on June 25, 2024, starting at 9:00 a.m. PDT, 12:00 p.m. EDT. This virtual event will focus on the evolving fintech industry, featuring emerging companies within specialty finance, payments and real estate that have integrated advanced technology into their business models. This event and its recorded replay are intended for institutions and members of M-Vest only. Those interested may sign up to bec
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their participation in the iAccess Alpha Buyside Best Ideas Summer Conference, June 25-26, 2024. Jeff Baker, Paysign's Chief Financial Officer, will deliver a presentation at 2:30 p.m. EDT on June 25, and is available to host one-on-one meetings the following day, June 26. Investors interested in registering or learning more may visit the conference website here. The presentation will be webcast and available for replay here. About iAccess Alpha iAccess Alpha hosts virtual investor confer
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing, today announced their participation in the Sidoti Small-Cap Virtual Investor Conference, taking place June 12-13, 2024. Jeff Baker, Paysign's Chief Financial Officer, will be available for one-on-one and small group meetings with investors during the event. To register or learn more about the conference, click here. About Sidoti In 2023, Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to mor
First quarter 2024 total revenues of $13.2 million, up 30% from first quarter 2023First quarter 2024 net income of $309 thousand, or diluted earnings per share of $0.01, versus net loss of $160 thousand, or diluted earnings per share of $(0.00) for first quarter 2023First quarter 2024 Adjusted EBITDA of $1.7 million, up 135% from $720 thousand for first quarter 2023, while diluted Adjusted EBITDA per share was $0.03 versus $0.01 for first quarter 20231Total plasma center count increased by five net new centers during first quarter 2024, exiting the quarter with 469 centers, contributing to an 11% increase in plasma revenue versus the same period last yearAdded 10 net new patient affordabilit
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
10-Q - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
S-8 - Paysign, Inc. (0001496443) (Filer)
S-8 POS - Paysign, Inc. (0001496443) (Filer)
S-8 - Paysign, Inc. (0001496443) (Filer)
10-Q - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
10-Q - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde
First quarter 2024 total revenues of $13.2 million, up 30% from first quarter 2023First quarter 2024 net income of $309 thousand, or diluted earnings per share of $0.01, versus net loss of $160 thousand, or diluted earnings per share of $(0.00) for first quarter 2023First quarter 2024 Adjusted EBITDA of $1.7 million, up 135% from $720 thousand for first quarter 2023, while diluted Adjusted EBITDA per share was $0.03 versus $0.01 for first quarter 20231Total plasma center count increased by five net new centers during first quarter 2024, exiting the quarter with 469 centers, contributing to an 11% increase in plasma revenue versus the same period last yearAdded 10 net new patient affordabilit
For the Full YearFull-year 2023 total revenues of $47.3 million, up 24% from full-year 2022Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share of $0.02 for full-year 2022Full-year 2023 Adjusted EBITDA of $6.7 million, up 21% from $5.5 million a year ago, while diluted Adjusted EBITDA per share was $0.12 versus $0.10 for full-year 20221Total plasma center count increased by 20 during 2023, exiting the year with 464 centers, contributing to a 21% increase in plasma revenue versus the same period last yearLaunched 24 net new patient affordability programs during 2023, exiting the year with 43 active
Third quarter total revenues of $12.4 million, an increase of 17% compared to third quarter 2022Third quarter net income of $1.1 million and diluted income per share of $0.02Third quarter Adjusted EBITDA of $2.3 million, an increase of 22% compared to third quarter 2022, and diluted Adjusted EBITDA per share of $0.04, unchanged from third quarter 20221Added 19 net new plasma donation centers during the third quarter, exiting the quarter with 462 centers, leading to a 13% increase in plasma revenue over the same period last yearLaunched three new patient affordability programs during the third quarter, exiting the quarter with 34 active programs, leading to a 142% increase in pharma patient a
Second quarter total revenues of $11.0 million, an increase of 28% compared to second quarter 2022Second quarter net loss of ($0.1) million and diluted loss per share of ($0.00)Second quarter Adjusted EBITDA of $1.1 million, an increase of 23% compared to second quarter 2022, and diluted Adjusted EBITDA per share of $0.02, unchanged from second quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release)Added four net new plasma donation centers during the second quarter, exiting the quarter with 443 centersLaunched fiv
First quarter total revenues of $10.1 million, up 23% from first quarter 2022First quarter net loss of ($0.2) million, or diluted loss per share of ($0.00)First quarter Adjusted EBITDA of $0.7 million, down 22% from $0.9 million a year ago, while diluted Adjusted EBITDA per share was $0.01 versus $0.02 for the first quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release)Added 10 plasma donation centers during the first quarter, exiting the quarter with 439 centersLaunched seven new patient affordability programs du
Company's Board Authorizes $5 Million Share Repurchase Program For the Full Year Full-year 2022 total revenues of $38.0 million, up 29% from full-year 2021 Full-year 2022 net income of $1.0 million, or diluted earnings per share of $0.02 Full-year 2022 Adjusted EBITDA of $5.5 million, up 175% from $2.0 million a year ago, while diluted Adjusted EBITDA per share was $0.10 versus $0.04 for full-year 2021 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of Net Income to Adjusted EBITDA at the end of the press release) Added 78 net plasma donation centers during 2022, exiting t
Third quarter total revenues of $10.6 million, an increase of $2.8 million (36.4%) from third quarter 2021 Third quarter net income of $0.85 million, or diluted earnings per share of $0.02 Third quarter Adjusted EBITDA of $1.9 million, or diluted Adjusted EBITDA per share of $0.04 (Adjusted EBITDA is a non-GAAP metric used by management to gauge the operating performance of the business – See reconciliation of Net Income to Adjusted EBITDA at the end of the press release) Added 13 plasma donation centers during the third quarter, bringing the year-to-date total additions to 84 Third quarter gross dollar load volume up 57.6% versus the year-ago period and up 23.1% versus the previou
Second quarter total revenues of $8.6 million, an increase of $1.9 million (29%) from second quarter 2021 Second quarter net loss of $0.2 million, or diluted net loss per share of ($0.00) Second quarter Adjusted EBITDA of $0.9 million, or diluted Adjusted EBITDA per share of $0.02 Added 62 plasma donation centers during the second quarter bringing the first half total additions to 71 Second quarter gross dollar load volume up 40.5% versus the year-ago period and 16.1% versus the previous quarter Second quarter purchase volume was up 45.7% versus the year-ago period and 26.8% versus the previous quarter Engaged Moss Adams LLP as the company's independent registered public accoun
First quarter total revenues of $8.2 million, an increase of $1.9 million from first quarter 2021 First quarter net loss of $0.3 million, or diluted net loss per share of ($0.01) First quarter adjusted EBITDA of $0.9 million, or diluted adjusted EBITDA per share of $0.02 First quarter gross dollar load volume up 16.2% versus the year-ago period and 7.6% versus the previous quarter First quarter purchase volume up 24.7% versus the year-ago period First quarter unrestricted cash increased by $1.1 million to $8.5 million Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated p